Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours

Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation

David L. Lacey, Emma Timms, Hong‐Lin Tan et al. · Cell · 1998 · 5.5K citations · Full text

Medicine, Cell Biology, Bone Metabolism +13

Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density

W. Scott Simonet, Dave Lacey, Colin R. Dunstan et al. · Cell · 1997 · 5.1K citations · Full text

Medicine, Biochemistry, Molecular Biology +13

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Hisataka Yasuda, Nobuyuki Shima, N. Nakagawa et al. · Proceedings of the National Academy of Sciences · 1998 · 4.3K citations

Medicine, Cell Biology, Molecular Biology +15

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

Dirk Anderson, Eugene Maraskovsky, William L. Billingsley et al. · Nature · 1997 · 2.3K citations

Life Sciences, Immunology, Molecular Biology +16

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Karim Fizazi, Michael A. Carducci, Matthew R. Smith et al. · The Lancet · 2011 · 2K citations · Full text

Medicine, Oncology, Urology +17